Gufic Biosciences fell 5.87% to Rs 420.85 after the company's consolidated net profit declined 6.03% to Rs 21.8 crore on 4.98% fall in revenue from operations to Rs 204.17 crore in Q2 FY25 over Q2 FY24.
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter.Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review.
EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24.
Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
 "Nitin Gadkari, Nitin, Gadkari")
 "Hero Motocorp, Karizma ZMR 2018")
 "Manipur")
 "debt funds, mutual funds, investment, markets, regulator")
 "Stock Market, Market, Crash, Funds, up, Stock, Gain, Lost, decline, statistic, Crisis, Capital, BSE, NSE")
